

## **CHAPTER ONE: EXECUTIVE SUMMARY**

- Scope and Methodolgy
- Introduction
- Current Stem Cell Therapies
- Developmental Stem Cell Therapies
- Issues In Stem Cell Research
- Stem Cell Forecasts

## **CHAPTER TWO: INTRODUCTION**

- The Promise of Stem Cells In Medical Treatment
- Types of Stem Cells
- Embryonic Stem Cells
- Adult Stem Cells
- Cord Blood Stem Cells
- Stem Cell Harvesting
- Embryonic Stem Cells
- Therapeutic Cloning
- Unfertilized Eggs
- Adult Stem Cells
- Leukapheresis
- Peripheral Blood
- Cord Blood Stem Cells
- Transplantation Approaches
- Autologous Transplantation
- Allogenic Transplantation
- Transplantation Procedures
- Cancerous Stem Cells
- Other Harmful Stem Cells
- Stem Cells in Drug Development
- Stem Cell Therapeutics
- Stem Cells Targeting Drugs
- Stem Cell Generated Organs

## **CHAPTER THREE: CURRENT STEM CELL THERAPIES**

- Cancer
- Leukemia
- Gene Therapy
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Non Cancerous Diseases
- Aplastic anemia
- Immunodeficiency

Lupus  
Sickle Cell Disease  
Other Conditions

## **CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES**

Alzheimer's Disease  
Arthritis  
Bladder Disease  
Burns  
Cancer  
Cardiovascular Conditions  
Critical Limb Ischemia  
Diabetes  
Esophageal Disease  
Incontinence  
Infertility  
Intestinal Disease  
Liver Failure  
Lung Disease  
Multiple Sclerosis  
Orthopedics  
Osteoporosis  
Parkinson's Disease  
Sickle Cell Disease  
Tooth Disease  
Wrinkles/Aging Skin

## **CHAPTER FIVE: STEM CELL FORECASTS**

Best Case  
Stem Cell Therapeutics  
Umbilical Cord Blood Banking  
Fees Related to Drug Development  
Most Likely Case  
Stem Cell Therapeutics  
Umbilical Cord Blood Banking  
Fees Related to Drug Development  
Worst Case  
Stem Cell Therapeutics  
Umbilical Cord Blood Banking  
Fees Related to Drug Development

## **CHAPTER SIX: ISSUES IN STEM CELL RESEARCH**

Ethical Questions

U.S. - State and Federal Initiatives  
Research Funding  
Federal Funding  
State Funding  
Cord Blood Initiatives  
International Initiatives  
Stem Cell Patents  
Other Healthcare Regulations

## **LIST OF EXHIBITS**

### **CHAPTER ONE: EXECUTIVE SUMMARY**

Table 1-1 Total Market for Stem Cell Technologies in \$ Millions, 2010 - 2020  
Table 1-2 Stem Cell Therapeutics Market in \$ Millions, 2010 - 2020  
Table 1-3 Total Market for Cord Blood Banking Fees in \$ Millions, 2010 - 2020  
Table 1-4 Total Market for Stem Cell Drug Development Technologies in \$ Millions, 2010 - 2020  
Figure 1-1 Total Market for Stem Cells - Most Likely Case in \$ Millions, 2010 – 2020

### **CHAPTER TWO: INTRODUCTION**

Table 2-1 Established and Emerging Artificial Organ Products by Market Segment, 2010

### **CHAPTER THREE: CURRENT STEM CELL THERAPIES**

Table 3-1 Types of Leukemia, 2011

### **CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES**

Table 4-1 Global Disease Populations Addressed by Potential Stem Cell Therapies, 2011  
Table 4-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020  
Table 4-3 Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2010 and 2020  
Table 4-4 Features and Types of Urinary Incontinence, 2011  
Table 4-5 Types and Causes of Male Infertility, 2011  
Table 4-6 Common Diseases of the Lungs, 2011

### **CHAPTER FIVE: STEM CELL FORECASTS**

Table 5-1 Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2011  
Table 5-2 Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020

Table 5-3 Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in \$ Millions, 2010 - 2020

Table 5-4 131 Best Case: Cord Blood Banking Revenues in \$ Millions, 2007 - 2020

Table 5-5 Best Case: Stem Cell-Based Drug Development Technology Fees, 2010 - 2020

Table 5-6 Best Case: Stem Cell-Based Drug Development Technology Fees in \$ Millions, 2010 - 2020

Table 5-7 Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020

Table 5-8 Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in \$ Millions, 2010 - 2020

Table 5-9 Most Likely Case: Cord Blood Banking Revenues in \$ Millions, 2010 - 2020

Table 5-10 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010 - 2020

Table 5-11 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in \$ Millions, 2010 - 2020

Table 5-12 Worst Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020

Table 5-13 Worst Case: Revenues for Proprietary Stem Cell Therapies by Disease in \$ Millions, 2010 - 2020

Table 5-14 Worst Case: Cord Blood Banking Revenues in \$ Millions, 2010-2020

Table 5-15 Worst Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010-2020

Table 5-16 Worst Case: Stem Cell-Based Drug Development Technology Fees in \$ Millions 2010-2020

## **CHAPTER SIX: ISSUES IN STEM CELL RESEARCH**

Table 6-1 NIH Funding for Stem Cell Research, 2002 - 2010 in \$ Million

Table 6-2 U.S. State Embryonic & Fetal Research Laws

Table 6-3 Positions on Human ES Cell Research by Country, 2011

Table 6-4 EU Laws on hESC Research by Country